AMH and breast carcinoma: reported that the median AMH levels were lower in patients who received FEC sequentially with docetaxel than in patients who received FEC chemotherapy alone in women below 35 years with early breast cancer, indicating the combined use of paclitaxel increased the risk of ovarian damage.